Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Total Debt (2022 - 2025)

60 Degrees Pharmaceuticals (SXTP) has disclosed Total Debt for 4 consecutive years, with $797275.0 as the latest value for Q3 2025.

  • On a quarterly basis, Total Debt rose 27.82% to $797275.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $797275.0, a 27.82% increase, with the full-year FY2024 number at $640830.0, down 72.22% from a year prior.
  • Total Debt was $797275.0 for Q3 2025 at 60 Degrees Pharmaceuticals, up from $776172.0 in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $3.3 million in Q2 2023 to a low of $565949.0 in Q1 2024.
  • A 4-year average of $1.3 million and a median of $776172.0 in 2025 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: crashed 82.84% in 2024, then surged 36.88% in 2025.
  • 60 Degrees Pharmaceuticals' Total Debt stood at $1.9 million in 2022, then increased by 18.65% to $2.3 million in 2023, then tumbled by 72.22% to $640830.0 in 2024, then increased by 24.41% to $797275.0 in 2025.
  • Per Business Quant, the three most recent readings for SXTP's Total Debt are $797275.0 (Q3 2025), $776172.0 (Q2 2025), and $635725.0 (Q1 2025).